Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T87024
(Former ID: TTDC00180)
|
|||||
Target Name |
Amyloid beta A4 protein (APP)
|
|||||
Synonyms |
Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
|
|||||
Gene Name |
APP
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Diagnostic imaging [ICD-11: N.A.] | |||||
Function |
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
Click to Show/Hide
|
|||||
BioChemical Class |
Amyloid beta-protein peptide
|
|||||
UniProt ID | ||||||
Sequence |
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTK
TCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG EFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFR GVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPC RAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARD PVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQA KNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYER MNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTET KTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTN IKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T01E8J |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Florbetapir F-18 | Drug Info | Approved | Diagnostic imaging | [2] | |
Clinical Trial Drug(s) | [+] 31 Clinical Trial Drugs | + | ||||
1 | ALZT-OP1 | Drug Info | Phase 3 | Alzheimer disease | [3], [4] | |
2 | Bapineuzumab | Drug Info | Phase 3 | Alzheimer disease | [5], [6] | |
3 | BIIB037 | Drug Info | Phase 3 | Alzheimer disease | [7] | |
4 | Crenezumab | Drug Info | Phase 3 | Alzheimer disease | [3], [4] | |
5 | Curcumin | Drug Info | Phase 3 | Solid tumour/cancer | [8], [9] | |
6 | Gantenerumab | Drug Info | Phase 3 | Alzheimer disease | [10], [11] | |
7 | NI-101 | Drug Info | Phase 3 | Alzheimer disease | [7], [12] | |
8 | PF-03084014 | Drug Info | Phase 3 | Desmoid tumour | [13] | |
9 | Solanezumab | Drug Info | Phase 3 | Alzheimer disease | [14], [15] | |
10 | Tramiprosate | Drug Info | Phase 3 | Alzheimer disease | [16] | |
11 | CAD-106 | Drug Info | Phase 2/3 | Alzheimer disease | [17] | |
12 | ALZ-801 | Drug Info | Phase 2 | Alzheimer disease | [3], [4] | |
13 | AN-1792 | Drug Info | Phase 2 | Alzheimer disease | [18] | |
14 | BAN2401 | Drug Info | Phase 2 | Alzheimer disease | [19] | |
15 | FRM-0962 | Drug Info | Phase 2 | Alzheimer disease | [20] | |
16 | GSK933776A | Drug Info | Phase 2 | Macular degeneration | [21] | |
17 | Myo-inositol | Drug Info | Phase 2 | Alzheimer disease | [22] | |
18 | NIC5-15 | Drug Info | Phase 2 | Alzheimer disease | [23] | |
19 | Ponezumab | Drug Info | Phase 2 | Alzheimer disease | [24] | |
20 | T-817MA | Drug Info | Phase 2 | Alzheimer disease | [25] | |
21 | UB-311 | Drug Info | Phase 2 | Alzheimer disease | [26] | |
22 | ACI-24 | Drug Info | Phase 1/2 | Alzheimer disease | [27] | |
23 | EB-101 | Drug Info | Phase 1/2 | Dystrophic epidermolysis bullosa | [28] | |
24 | 11C-6-Me-BTA-1 | Drug Info | Phase 1 | Alzheimer disease | [29] | |
25 | 11C-AZD-2184 | Drug Info | Phase 1 | Alzheimer disease | [30] | |
26 | AAB-003/PF-05236812 | Drug Info | Phase 1 | Alzheimer disease | [31] | |
27 | Affitope AD-01 | Drug Info | Phase 1 | Alzheimer disease | [32] | |
28 | Anti-N3pG-Abeta antibody | Drug Info | Phase 1 | Alzheimer disease | [33] | |
29 | DWP-09031 | Drug Info | Phase 1 | Alzheimer disease | [34] | |
30 | SAR228810 | Drug Info | Phase 1 | Alzheimer disease | [35] | |
31 | Systebryl | Drug Info | Phase 1 | Amyloidosis | [36] | |
Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
1 | Affitope AD-02 | Drug Info | Discontinued in Phase 2 | Alzheimer disease | [37] | |
2 | RN6G | Drug Info | Discontinued in Phase 2 | Age-related macular degeneration | [38] | |
3 | PF-05236812 | Drug Info | Discontinued in Phase 1 | Alzheimer disease | [39] | |
Preclinical Drug(s) | [+] 3 Preclinical Drugs | + | ||||
1 | AAB-002 | Drug Info | Phase 0 | Alzheimer disease | [40] | |
2 | NN-818 | Drug Info | Preclinical | Brain injury | [41] | |
3 | Pepticlere | Drug Info | Preclinical | Alzheimer disease | [42] | |
Mode of Action | [+] 5 Modes of Action | + | ||||
Modulator | [+] 20 Modulator drugs | + | ||||
1 | Florbetapir F-18 | Drug Info | [1] | |||
2 | BIIB037 | Drug Info | [44] | |||
3 | Crenezumab | Drug Info | [45] | |||
4 | Solanezumab | Drug Info | [49] | |||
5 | BAN2401 | Drug Info | [54] | |||
6 | FRM-0962 | Drug Info | [55] | |||
7 | GSK933776A | Drug Info | [56] | |||
8 | UB-311 | Drug Info | [59] | |||
9 | 11C-6-Me-BTA-1 | Drug Info | [61] | |||
10 | AAB-003/PF-05236812 | Drug Info | [45] | |||
11 | AAB-002 | Drug Info | [45] | |||
12 | NN-818 | Drug Info | [45] | |||
13 | 123I-DRM-106 | Drug Info | [45] | |||
14 | 18F-AV-45 dimer | Drug Info | [45] | |||
15 | AS-602704 | Drug Info | [73] | |||
16 | BAN-2203 | Drug Info | [45] | |||
17 | EDN-OL1 | Drug Info | [45] | |||
18 | Gamma-secretase modulators | Drug Info | [45] | |||
19 | PA-1637 | Drug Info | [45] | |||
20 | TKP-1001 | Drug Info | [45] | |||
Inhibitor | [+] 62 Inhibitor drugs | + | ||||
1 | ALZT-OP1 | Drug Info | [4] | |||
2 | Curcumin | Drug Info | [46] | |||
3 | PF-03084014 | Drug Info | [48] | |||
4 | ALZ-801 | Drug Info | [52] | |||
5 | AN-1792 | Drug Info | [53] | |||
6 | Myo-inositol | Drug Info | [22] | |||
7 | NIC5-15 | Drug Info | [57] | |||
8 | T-817MA | Drug Info | [3], [4] | |||
9 | DWP-09031 | Drug Info | [45] | |||
10 | Systebryl | Drug Info | [45] | |||
11 | RN6G | Drug Info | [67] | |||
12 | PF-05236812 | Drug Info | [44] | |||
13 | Pepticlere | Drug Info | [68] | |||
14 | 1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene | Drug Info | [69] | |||
15 | 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene | Drug Info | [69] | |||
16 | 1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene | Drug Info | [69] | |||
17 | 1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene | Drug Info | [69] | |||
18 | 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene | Drug Info | [69] | |||
19 | 2,5-bis(2-methoxyphenyl)thiophene | Drug Info | [70] | |||
20 | 2,5-bis(4-Hydroxyphenyl)thiophene | Drug Info | [70] | |||
21 | 2,5-bis(4-methoxyphenyl)thiophene | Drug Info | [70] | |||
22 | 2,5-bis(4-nitrophenyl)thiophene | Drug Info | [70] | |||
23 | 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol | Drug Info | [69] | |||
24 | 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene | Drug Info | [70] | |||
25 | 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol | Drug Info | [70] | |||
26 | 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine | Drug Info | [70] | |||
27 | 4-(5-(4-aminophenyl)thiophen-2-yl)phenol | Drug Info | [70] | |||
28 | 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine | Drug Info | [70] | |||
29 | 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol | Drug Info | [70] | |||
30 | 5-hydroxy-2-(4-aminophenyl)benzofuran | Drug Info | [71] | |||
31 | 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran | Drug Info | [71] | |||
32 | 5-hydroxy-2-(4-methylaminophenyl)benzofuran | Drug Info | [71] | |||
33 | 5-methoxy-2-(4-aminophenyl)benzofuran | Drug Info | [71] | |||
34 | 5-methoxy-2-(4-dimethylaminophenyl)benzofuran | Drug Info | [71] | |||
35 | 5-methoxy-2-(4-methylaminophenyl)benzofuran | Drug Info | [71] | |||
36 | 6-iodo-4'-dimethyaminoflavone | Drug Info | [72] | |||
37 | 6-iodo-4'-hydroxyflavone | Drug Info | [72] | |||
38 | 6-iodo-4'-methoxyflavone | Drug Info | [72] | |||
39 | 6-iodo-4'-methylaminoflavone | Drug Info | [72] | |||
40 | A-887755 | Drug Info | [45] | |||
41 | Abloid | Drug Info | [45] | |||
42 | ACI-636 | Drug Info | [45] | |||
43 | ANA-5 | Drug Info | [45] | |||
44 | Anticalin | Drug Info | [45] | |||
45 | ARC-069 | Drug Info | [45] | |||
46 | ARN-2966 | Drug Info | [45] | |||
47 | AZ4800 | Drug Info | [74] | |||
48 | Chrysamine -G | Drug Info | [46] | |||
49 | CT-003230 | Drug Info | [45] | |||
50 | DBT-1339 | Drug Info | [45] | |||
51 | DEHYDROZINGERONE | Drug Info | [46] | |||
52 | ELND-007 | Drug Info | [75] | |||
53 | KMS-88009 | Drug Info | [45] | |||
54 | Methionine Sulfoxide | Drug Info | [77] | |||
55 | SB-13 | Drug Info | [69] | |||
56 | SEM-606 | Drug Info | [45] | |||
57 | SEN-1500 | Drug Info | [45] | |||
58 | SP-08 | Drug Info | [45] | |||
59 | SR-973 | Drug Info | [78] | |||
60 | Turmeric extracts | Drug Info | [45] | |||
61 | VK-11 | Drug Info | [45] | |||
62 | VK-12 | Drug Info | [45] | |||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | Tramiprosate | Drug Info | [50] | |||
Binder | [+] 1 Binder drugs | + | ||||
1 | 11C-AZD-2184 | Drug Info | [62] | |||
Agonist | [+] 1 Agonist drugs | + | ||||
1 | CD45RB | Drug Info | [45] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
1 | Notch signaling pathway | |||||
2 | Alzheimer's disease | |||||
Reactome | [+] 8 Reactome Pathways | + | ||||
1 | Nuclear signaling by ERBB4 | |||||
2 | Degradation of the extracellular matrix | |||||
3 | Regulated proteolysis of p75NTR | |||||
4 | NRIF signals cell death from the nucleus | |||||
5 | Activated NOTCH1 Transmits Signal to the Nucleus | |||||
6 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
7 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
8 | EPH-ephrin mediated repulsion of cells | |||||
WikiPathways | [+] 9 WikiPathways | + | ||||
1 | Notch Signaling Pathway | |||||
2 | Signaling by ERBB4 | |||||
3 | Signaling by NOTCH3 | |||||
4 | Signaling by NOTCH4 | |||||
5 | Signaling by NOTCH1 | |||||
6 | Signaling by NOTCH2 | |||||
7 | Notch Signaling Pathway | |||||
8 | Alzheimers Disease | |||||
9 | Signalling by NGF |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6930). | |||||
REF 6 | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33. | |||||
REF 7 | ClinicalTrials.gov (NCT02484547) 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease. | |||||
REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000). | |||||
REF 9 | Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68. | |||||
REF 10 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6933). | |||||
REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015121) | |||||
REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8325). | |||||
REF 13 | ClinicalTrials.gov (NCT03785964) Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi). U.S. National Institutes of Health. | |||||
REF 14 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932). | |||||
REF 15 | ClinicalTrials.gov (NCT01900665) Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo. U.S. National Institutes of Health. | |||||
REF 16 | ClinicalTrials.gov (NCT00314912) Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 17 | ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease. | |||||
REF 18 | ClinicalTrials.gov (NCT00021723) Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT01767311) A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 20 | Clinical pipeline report, company report or official report of Forum pharmaceuticals. | |||||
REF 21 | ClinicalTrials.gov (NCT01342926) Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. U.S. National Institutes of Health. | |||||
REF 22 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 23 | ClinicalTrials.gov (NCT01928420) A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 24 | ClinicalTrials.gov (NCT01821118) Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy. U.S. National Institutes of Health. | |||||
REF 25 | ClinicalTrials.gov (NCT02079909) Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202). U.S. National Institutes of Health. | |||||
REF 26 | ClinicalTrials.gov (NCT02551809) Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients. | |||||
REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031074) | |||||
REF 28 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 29 | List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegener Dis. 2012;9(4):210-83. | |||||
REF 30 | ClinicalTrials.gov (NCT00838877) Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for A Amyloid. U.S. National Institutes of Health. | |||||
REF 31 | ClinicalTrials.gov (NCT01369225) Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 32 | ClinicalTrials.gov (NCT00495417) Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 33 | ClinicalTrials.gov (NCT01837641) A Study of LY3002813 in Participants With Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 34 | ClinicalTrials.gov (NCT01522586) Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031. U.S. National Institutes of Health. | |||||
REF 35 | ClinicalTrials.gov (NCT01485302) Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients. U.S. National Institutes of Health. | |||||
REF 36 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 37 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029150) | |||||
REF 38 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031573) | |||||
REF 39 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030748) | |||||
REF 40 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024936) | |||||
REF 41 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020811) | |||||
REF 42 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023984) | |||||
REF 43 | Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82. | |||||
REF 44 | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. | |||||
REF 45 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). | |||||
REF 46 | Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. | |||||
REF 47 | Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479. | |||||
REF 48 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 49 | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. | |||||
REF 50 | Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. | |||||
REF 51 | The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31. | |||||
REF 52 | Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012. | |||||
REF 53 | Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63. | |||||
REF 54 | The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88. | |||||
REF 55 | Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014 | |||||
REF 56 | Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569. | |||||
REF 57 | Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20. | |||||
REF 58 | Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. | |||||
REF 59 | Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7. | |||||
REF 60 | Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36. | |||||
REF 61 | Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80. | |||||
REF 62 | Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593. | |||||
REF 63 | Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808. | |||||
REF 64 | LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co. | |||||
REF 65 | SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809. | |||||
REF 66 | Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. | |||||
REF 67 | Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29. | |||||
REF 68 | Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc. | |||||
REF 69 | Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. | |||||
REF 70 | Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. | |||||
REF 71 | Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. | |||||
REF 72 | Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. | |||||
REF 73 | Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm. 2007 Jan;33(1):71-7. | |||||
REF 74 | First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9. | |||||
REF 75 | Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396. | |||||
REF 76 | Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33. | |||||
REF 77 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 78 | Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.